title: Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke.
abstract: Procoagulant or impaired fibrinolytic states as well as inflammatory reactions mediated by cytokines are likely involved in the pathogenesis of acute ischemic stroke. We examined the potential relationship between interleukin 6 (IL-6) and hemostatic markers. The procoagulant and fibrinolytic states were assessed in 46 patients with acute stroke by measuring plasma levels of plasminogen activator inhibitor-1 (PAI-1), thrombin-antithrombin complex (TAT), and plasminogen-antiplasmin complex (PAP). Circulating IL-6 levels were measured using ELISA (Quantikine, R and D systems, MN, USA). Circulating IL-6 (mean, 26.5 pg/mL) and PAI-1 (mean, 19.9 ng/mL) levels were higher in patients with acute stroke than in healthy subjects (mean, 3.0 pg/mL, 10.4 ng/mL, respectively). TAT levels were statistically different according to the etiologic subtypes of stroke (atherogenic, 2.5 ng/mL; lacunar 3.2 ng/mL; cardiogenic 9.9 ng/mL, p = 0.021). Neither procoagulant levels nor fibrinolytic markers significantly correlated with circulating IL-6 levels. Our findings suggest that elevated proinflammatory cytokines during the initial hours of ischemic stroke may be an independent pathogenic factor or a consequence of the thrombotic event with no relationship to the procoagulant or fibrinolytic states.
authors.affiliation: Department of Laboratory Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
authors.forename: Jae Woo
authors.initials: JW
authors.lastname: Song
authors.forename: Kyung Soon
authors.initials: KS
authors.lastname: Song
authors.forename: Jong Rak
authors.initials: JR
authors.lastname: Choi
authors.forename: Shin Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Ji-Hyuk
authors.initials: JH
authors.lastname: Rhee
mesh_terms: D000208:Acute Disease; D000368:Aged; D000991:Antithrombins / Q000737:chemistry; D001779:Blood Coagulation Factors / Q000378:metabolism; D003029:Coagulants / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D015850:Interleukin-6 / Q000097:blood* / Q000378:metabolism; D007511:Ischemia / Q000097:blood* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010743:Phospholipids / Q000737:chemistry; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D020521:Stroke / Q000097:blood* / Q000473:pathology*; D013917:Thrombin / Q000737:chemistry; D015912:Thrombolytic Therapy; D013927:Thrombosis
chemical_list: D000991:Antithrombins; D001779:Blood Coagulation Factors; D003029:Coagulants; D016207:Cytokines; D015850:Interleukin-6; D010743:Phospholipids; D017395:Plasminogen Activator Inhibitor 1; D013917:Thrombin